Abstract
This prospective clinical study was to compare the effect of panretinal photocoagulation (PRP) associated with intravitreal conbercept injections versus PRP alone in the treatment of proliferative diabetic retinopathy (PDR). For each of 15 patients included, one eye was randomly assigned to receive treatment with PRP, and the other eye received conbercept combined PRP. Ophthalmic examinations, optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) were performed at baseline and at each monthly visit until 6 months. Fluorescein angiography (FA) was acquired at baseline, 3 months and 6 months. Between group and within group analysis was done by using generalized estimating equations (GEE). The combination group had a significant decrease of neovascularization (NV) leakage area than the PRP group at month 3 and month 6 after treatment, and a better best-corrected visual acuity (BCVA) during the first three months. Within-group analysis indicated a significant decrease in NV leakage at month 3 and month 6 in both groups, and a significant increase in BCVA at 1 month in the combination group. In summary, the combination of intravitreal injection of conbercept and PRP can significantly reduce the NV of PDR patients and achieve better BCVA during the drug’s lifespan compared with PRP alone.
Highlights
This prospective clinical study was to compare the effect of panretinal photocoagulation (PRP) associated with intravitreal conbercept injections versus PRP alone in the treatment of proliferative diabetic retinopathy (PDR)
Previous studies found that PRP combined with anti-VEGF agents such as ranibizumab was more effective for NV regression than PRP alone;[4,5,6] but there was no unified scheme in different studies
We examined the following outcomes regarding whether there was a difference in changes from baseline between the two treatment groups: NV leakage area, total regression rate of NV, best-corrected visual acuity (BCVA), Central retinal thickness (CRT), foveal avascular zone (FAZ), and flow density (FD)
Summary
This prospective clinical study was to compare the effect of panretinal photocoagulation (PRP) associated with intravitreal conbercept injections versus PRP alone in the treatment of proliferative diabetic retinopathy (PDR). Conbercept is a recombinant fusion protein which consists of the 2nd Ig domain of VEGFR1 and the 3rd and 4th Ig domains of VEGFR2 combined with the constant region, i.e, Fragment of crystallizable (Fc) of human IgG17,8 It has been approved by the Chinese Food and Drug Administration for the treatment of wet age-related macular degeneration, diabetic macular edema and choroid neovascularization secondary to pathologic myopia. Examining the short-tern changes of retinal neovascularization to PRP or Conbercept may contribute to the determination of the efficacy of different treatment options and the optimal retreatment time
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
